Biocompatibility of Highly Fluorinated Liquids Used in Ophthalmic Surgery

Fluorine and Health

Volumn , Issue , 2008, Pages 421-445

  Menz, Dirk Henning ^a   Dresp, Joachim H ^b  

^a PHARMPUR GMBH   (Germany)

^b BAUSCH AND LOMB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882811118     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-444-53086-8.00010-2     Document Type: Chapter

References (55)

1. Chang S., Ozmert E., Zimmerman N.J. Intraoperative perfluorocarbon liquids in the management of proliferative retinopathy. Am. J. Ophthalmol. 1988, 106:668-674.
2. Kuroda Y., Kawamura T., Suzuki Y. A new simple method for cold storage of the pancreas using perfluorochemicals. Transplantation 1988, 46:457.
3. Shaffer T.H., Rubenstein D., Moskowitz D., Delivoria-Papadopoulos M. Gaseous exchange and acid-base balance in premature lambs during liquid ventilation since birth. Pediatr. Res. 1976, 10:227-231.
4. Quintel M, Waschke K.F., Meinhardt J. Flüssigkeitsbeatmung mit Perfluorocarbon. Anästhesiol Intensivmed Notfallmed Schmerzther 1996, 31:461-469.
5. Withe D.C. Use of perfluorocarbons as wound treatment. US Patent No. 4,366169 1981.
6. Haidt S.J., Clark L.C., Ginsberg J. Liquid perfluorocarbon replacement of the eye. Invest. Ophthalmol. Vis. Sci. 1982, 22(Suppl.):233.
7. Chang S., Lincoff H., Zimmermann N.J., Fuchs W. Giant retinal tears. Surgical techniques and results using perfluorocarbon liquids. Arch. Ophthalmol. 1989, 107:761-766.
8. Miyamoto K., Refojo M.F., Tolentino F., Fournier G.A., Albert D.M. Fluorinated oils as exp. Vitreous substitutes. Arch. Ophthalmol. 1986, 104:1053-1056.
9. Eckardt C., Nicolai U. Klinische und histologische Befunde nach mehrwöchiger intraokularer Tamponade mit Perfluordekalin. Ophthalmologe 1993, 90:443-447.
10. Velikay M., Wedrich A., Stolba U., Datlinger P., Li Y., Binder S. Experimental long-term vitreous replacement with purified and non-purified perfluorodecalin. Am. J. Ophthalmol. 1993, 116:565-570.
11. Binder S., Velikay M., Wedrich A., Stolba U., Datlinger P. Die klinische Anwendung flüssiger Perfluorcarbone in der Netzhautchirurgie. Spektrum Augenheilkund. 1992, 6:4-7.
12. Williams D. Revisiting the definition of biocompatibility. Med. Device Technol. 2003, 14:10-13.
13. ISO 10993 standards for evaluating biocompatibility, ISO 10993-5, Biological evaluation of medical devices-Part 5: Tests for cytotoxicity: in vitro methods.
14. Clark L.C. Methods of treating disorders of the eye with liquid perfluorocarbons. US Patent No. 4,490351 1984.
15. Haidt S.J. Extraocular method of treating the eye with liquid perfluorocarbons. US Patent No. 4,452818 1984.
16. Peyman G.A., Schulman J.A., Sullivan B. Perfluorcarbon liquids in ophthalmology. Surv. Ophthalmol. 1995, 39:375-395.
17. ISO 14971, Medical device risk management.
18. Velikay M., Stolba U., Wedrich A., Li Y., Datlinger P., Binder S. The effect of chemical stability and purification of perfluorocarbon liquids in experimental extended-term vitreous substitutes. Graefes Arch. Clin. Exp. Ophthalmol. 1995, 233:26-30.
19. Gervits L.L. Perfluorocarbon-based blood substitutes: Russian experience 1994.
20. Meinert H. Method of purifying perfluorocarbons, and use of the perfluorocarbons thus purified. US Patent No. 5,563,306 1996.
21. Chang S., Sparrow J.R., Iwamoto T., Gershbein A., Ross R., Ortiz R. Experimental studies of tolerance to intravitreal perfluoro-n-octane liquid. Retina 1991, 11:367-374.
22. Nabih M., Peyman G.A., Clarc L.C. Experimental evaluation of perfluorophenantrene as high specific gravity vitreous substitute: A preliminary report. Ophthalmic Surg. 1989, 20:286-293.
23. Meinert H. Semifluorierte Alkane und ihre Verwendung. Patent Nr. DE 19536504 A1; PCT/EP96/03542 1995.
24. Lattes I., Feurer B., Guidetti B., Payrou V. Fluorinated organic compounds, ophthalmological applications thereof and method for making same. US Patent No. 6,040,485 2000.
25. Menz D.H. Fluorierte Alkane und ihre Verwendung. Patent Nr. DE 197 19 280 1997.
26. Meinert H., Roy T. Semifluorinated alkanes-a new class of compounds with outstanding properties for use in ophthalmology. Eur. J. Ophthalmol. 2000, 10:189-197.
27. Napoli M. Diblock and triblock semifluorinated n-alcanes: Preparations, structural aspects and applications. J. Fluorine Chem. 1996, 79:59-69.
28. Hoerauf H. Flüssige Hydrofluorkarbone als Netzhauttamponade und intraoperative Hilfsmittel in der Glaskörperchirurgie-Experimentelle Befunde und klinische Anwendung. Habilitationsschrift Lübeck 2003.
29. Roider J., Hoerauf H., Kobuch K., Gabel V.P. Clinical findings on the use of long-term heavy tamponades (semifluorinated alkanes and their oligomers) in complicated retinal detachment surgery. Graefes Arch. Clin. Exp. Ophthalmol. 2002, 240:965-971.
30. Kirchhof B., Sorgente N. Pathogenesis of proliferative vitreoretinopathy. Modulation of retinal pigment epithelial cell functions by vitreous and macrophages. Dev. Ophthalmol. 1989, 16:1-53.
31. Doi M., Refojo M.F. Histopathology of rabbit eyes with silicone-fluorosilicone copolymer oil as six months internal retinal tamponade. Exp. Eye Res. 1995, 61:469-478.
32. Nakamura K., Refojo M.F., Crabtree D.V., Leang F.L. Analysis and fractionation of silicone and fluorosilicone oils for intraocular use. Invest. Ophthalmol. Vis. Sci. 1990, 31:2059-2069.
33. Wolf S., Schön V., Meier P., Wiedemann P. Schweres Silikonöl als Endotamponade bei komplizierter Netzhautablösung. Ophthalmologe 2000, 104(Suppl. 1):45. (a).
34. Wolf S., Schön V., Meier P., Wiedemann P. Silicone Oil-RMN3 mixture ("Heavy Silicone Oil") as internal tamponade for complicated retinal detachment. Retina 2003, 23(Suppl. 3):335. (b).
35. Wong D., Van Meurs J.C., Stappler T., Groenewald C., Pearce I.A., McGalliard J.N., Manousakis E., Herbert E.N. A pilot study on the use of a perfluorohexyloctane/silicone oil solution as a heavier than water internal tamponade agent. Br. J. Ophthalmol. 2005, 89:662-665.
36. Winter M., Behrendt S., Menz D.H., Pfister G. Retinale Druckbelastung durch Perfluordekalin. Ophthalmologe 1999, 103(Suppl. 1):421.
37. Gabel V.P., Kobuch K., Hoerauf H., Menz D.H., Dresp J., Laqua H. Specific gravity, the cause of retinal damage induced by perfluorocarbon liquids?. Invest. Ophthalmol. Vis. Sci. 2000, 41(Suppl.):662.
38. Costa Gomes M.F., Deschamps J., Menz D.-H. Solubility of dioxygen in seven fluorinated liquids. J. Fluorine Chem. 2004, 125:1325-1329.
39. Kobuch K., Fuchs B., Tomi A., Roider J., Gabel V.P. The influence of O2 and Co2 concentrations in perfluorocarbon liquids as vitreous substitute on the retinal perfusion. IOVS abstract book 1999, 40:4052.
40. Fuchs B. Der Einfluß von verschiedenen synthetischen Glaskörperersatzstoffen auf den intravitrealen Sauerstoffpartialdruck. Inaugural Dissertation 2003, Regensburg.
41. Menz D.H. Side effects of ocular endotamponades caused by surface behaviors of fluorocarbons 2004, Poznan, Pologne.
42. Winter M., Winter C., Wiechens B. Quantification of intraocular retained perfluorodecaline after macroscopic removal. Graefes Arch. Clin. Exp. Ophthalmol. 1999, 237:153-156.
43. Wong D., Williams R.L., German M.J. Exchange of perfluorodecalin for gas or oil: A model for avoiding slippage. Graefes Arch. Clin. Exp. Ophthalmol. 1998, 236:234-237.
44. Groß U., Menz D.H., Kobuch K., Hoerauf H. Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie. Patent Nr. DE 19926890 2000, 8-41.
45. Kobuch K., Menz D.H., Hoerauf H., Dresp J.H., Gabel V.P. New substances for intraocular tamponades: Perfluorocarbon liquids, hydrofluorocarbon liquids and hydro-fluorocarbon-oligomers in vitreoretinal surgery. Graefes Arch. Clin. Exp. Ophthalmol. 2001, 239:635-642.
46. Kobuch K., Menz D.H., Gabel V.P. Retinologie heute 2000, 98-104. Ad. manum medici (publ.), München. G.K. Krieglstein (Ed.).
47. Winter M., Eberhardt W., Scholz C., Reichenbach A. Failure of potassium siphoning by Müller cells: A new hypothesis of perfluorocarbon liquid induced retinopathy. Invest. Ophthalmol. Vis. Sci. 2000, 41:256-261.
48. Winter M., Eckardt C., Havsteen B. Vitreous changes after contact with high-density substances: an in vitro experiment. Ger. J. Ophthalmol. 1992, 1:268A.
49. 8 endotamponade. ESEM and EDXA analysis 2003.
50. Malchiodi-Albedi F., Matteucci A., Formisano G., Paradisi S., Carnovale-Scalzo G., Scorcia G., Hoerauf H. Induction of apoptosis in rat retinal cell cultures by partially fluorinated alkanes. Am. J. Ophthalmol. 2005, 139:737-739.
51. Kirchhof B. Fluorkarbone in der Netzhaut-Glaskörperchirurgie. Ophthalmo Chirurgie 1999, 11:153-158.
52. Menz D.H., Dresp J.H. Plastically deformable implant. PCT/EPOO/05208, Appl. No. 2,377,155 2000.
53. Krafft M.P., Riess J.G. Stabile hochkonzentrierte Fluorkohlenwasserstoffgele. Angew. Chem. 1994, 106:1146-1147.
54. Hoerauf H., Menz D.H., Dresp J., John H., Moll R., Laqua H. Modification of vitreous serum albumin by hydrofluorocarbons as a cause of severe inflammatory reaction 2003.
55. Hoerauf H., Kobuch K., Dresp J., Menz D.H. Combined use of partially fluorinated alkanes, perfluorocarbon liquids and silicone oil-an experimental study. Graefes Arch. Clin. Exp. Ophthalmol. 2001, 239:373-381.